At the news
? BULLISHIMPACT 7/10 8-K filed May 13, 2026 at 16:22 ET
Precigen reported Q1 2026 revenue of $23.3M, massively up from $1.3M a year ago, driven by $21.6M in PAPZIMEOS product revenue in its first full commercial quarter. Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025, as the company transitions to a commercial-stage biopharma. The strong launch trajectory and cash position of $56.7M support management's expectation of reaching cash flow break-even by end of 2026.
- Q1 2026 total revenue of $23.3M, up from $1.3M in Q1 2025, driven by $21.6M in PAPZIMEOS net product revenue
- Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025
- Cash, cash equivalents, and investments totaled $56.7M as of March 31, 2026
- Approximately $25.7M in PAPZIMEOS-related accounts receivable not yet collected as of quarter-end
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access